The MNI forms promising Open Science partnership with Takeda | Montreal Neurological Institute and Hospital - McGill University

"Industry and academia team up for the benefit of people suffering from ALS A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide. The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI."